Entest (ETNI) 10-K 20 Dec 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2019	Dec. 16, 2019	Feb. 28, 2019
Document And Entity Information
Entity Registrant Name	ENTEST GROUP, INC.
Entity Central Index Key	0001449447
Document Type	10-K
Document Period End Date	Aug. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Public Float			$ 440,393
Entity Common Stock, Shares Outstanding		49,171,083
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Shell Company	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No

Balance Sheets

Balance Sheets - USD ($)	Aug. 31, 2019	Aug. 31, 2018
Current Assets
Cash		$ 267
Accrued Interest Receivable		1,040
Prepaid expenses		8,000
Total Current Assets		9,307
Total Assets		9,307
Current Liabilities
Accounts payable and accrued expenses	$ 11,474	218,417
Unearned rental income		17,000
Due to related party	21,197
Note payable		19,601
Total Current Liabilities	32,671	255,018
Total Liabilities	32,671	255,018
Stockholders' Deficit
Common stock: 500,000,000 shares authorized; $0.0001 par value; 49,171,083 shares issued and outstanding	4,917	4,917
Additional paid in capital	9,025,314	9,003,892
Accumulated deficit	(10,064,508)	(10,256,126)
Total Stockholders' Deficit	(32,671)	(245,711)
Total liabilities and Stockholder's Deficit		9,307
Series AA
Stockholders' Deficit
Preferred Stock
Series AAA
Stockholders' Deficit
Preferred Stock
Non-Voting Convertible Preferred Stock
Stockholders' Deficit
Preferred Stock	1,001,533	1,001,533
Series B
Stockholders' Deficit
Preferred Stock	$ 73	$ 73

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2019	Nov. 15, 2018	Aug. 31, 2018
Common stock, par value	$ 0.0001		$ 0.0001
Common stock, authorized	500,000,000		500,000,000
Common stock, issued	49,171,083		49,171,083
Common stock, outstanding	49,171,083	49,170,472	49,171,083
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	5,000,000		5,000,000
Series AA
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	100,000		100,000
Preferred stock, issued	667		667
Preferred stock, outstanding	667	667	667
Series AAA
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	300,000		300,000
Preferred stock, issued	534		534
Preferred stock, outstanding	534	534	534
Non-Voting Convertible Preferred Stock
Preferred stock, par value	$ 1		$ 1
Preferred stock, authorized	3,000,000		3,000,000
Preferred stock, issued	1,001,533		1,001,533
Preferred stock, outstanding	1,001,533	1,001,533	1,001,533
Series B
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	4,400,000		4,400,000
Preferred stock, issued	728,073		728,073
Preferred stock, outstanding	728,073	728,073	728,073

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating Expenses:
Research and development		949,584
Professional fees	22,689	310,020
General and administration	17,429	261,295
Total operating expenses	40,118	1,520,899
Operating Loss	(40,118)	(1,520,899)
Other Income (Expense):
Rental income	22,000	66,000
Gain on write off of accounts payable	23,629
Write off accrued interest receivable	(1,040)
Gain on deconsolidation of Zander		10,034
Equity in losses of Zander		(61,428)
Gain on disposition of Zander	188,589
Gain on sale of securities		30,000
Interest Income		132
Loss on disposition Entest Biomedical	(947)
Interest expense	(495)	(1,323)
Total Other Income (Expense)	231,736	43,415
Net Income (Loss) Before Income Tax	191,618	(1,477,484)
Income tax provision	0	0
Net Income (Loss)	$ 191,618	$ (1,477,484)
Basic income (loss) per common share	$ 0	$ (0.03)
Diluted income (loss) per common share	$ 0	$ (0.03)
Weighted average number of common shares outstanding
Basic	49,170,472	48,987,813
Diluted	120,708,543	48,987,813

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Series AA Preferred	Series AAA Preferred	Series B Preferred	Non Voting Convertible Preferred	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Non Controlling Interest In Subsidiary	Total
Beginning balance at Aug. 31, 2017			$ 73	$ 1,026,533	$ 4,667	$ 7,465,656	$ (8,721,496)	$ 185,050	$ 56,343	$ 16,826
Beginning balance (shares) at Aug. 31, 2017	667	534	728,073	1,026,533	46,671,083
Common Shares issued for conversion of Non-Voting Convertible Preferred Shares, Amount				$ (25,000)	$ 250	24,750
Common Shares issued for conversion of Non-Voting Convertible Preferred Shares				(25,000)	2,500,000
Common Shares of subsidiary issued for cash						1,400,000				1,400,000
Declaration and payment of property dividend						57,143	(57,143)
Non controlling interest in subsidiary						56,343			$ (56,343)
Accumlated other comprehensive loss								$ (185,050)		(185,050)
Net income (loss) for the year							(1,477,487)			(1,477,484)
Ending balance at Aug. 31, 2018			$ 73	$ 1,001,533	$ 4,917	9,003,892	(10,256,126)			(245,711)
Ending balance (shares) at Aug. 31, 2018	667	534	728,073	1,001,533	49,171,083
Contributed Capital						21,422				21,422
Net income (loss) for the year							191,618			191,618
Ending balance at Aug. 31, 2019			$ 73	$ 1,001,533	$ 4,917	$ 9,025,314	$ (10,064,508)			$ (32,671)
Ending balance (shares) at Aug. 31, 2019	667	534	728,073	1,001,533	49,171,083

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Cash Flows From Operating Activities:
Net income (loss)	$ 191,618	$ (1,477,484)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain attributable to deconsolidation		(10,034)
Cash lost in deconsolidation		(332,638)
Equity in losses of Zander		61,428
Loss on disposition Entest Biomedical	947
Gain on write off of accounts payable	(23,629)
Gain on disposition of Zander	(188,589)
Shareholder advances for operating expense	21,197
Changes in operating assets and liabilities:
Accrued interest receivable	1,040	(132)
Prepaid expenses	8,000	(117,388)
Accrued rental income receivable	(6,000)
Accounts payable and accrued expenses	(813)	369,147
Unearned rental income	(7,730)	17,000
Net Cash Used In Operating Activities	(3,959)	(1,490,101)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash received for divestiture of Entest Biomedical	1,937
Gain on sale of securities received prior to deconsolidation		(2,357)
Net Cash Provided (Used) by Investing Activities	1,937	(2,357)
Cash Flows From Financing Activities:
Contributed capital	1,821
Proceeds from common stock issued from subsidiary		1,400,000
Proceed from bank overdraft		66
Repayment of bank overdraft	(66)
Proceed from notes payable		6,100
Net Cash Provided by Financing Activities	1,755	1,406,166
Net Change in Cash	(267)	(86,292)
Cash at Beginning of Period	267	86,559
Cash at End of Period	0	267
Supplemental Cash Flow Information:
Cash paid for interest	0	0
Income tax provision	0	$ 0
Supplemental disclosure of non-cash financing activity
Debt Satisfied through Contributed Capital	$ 19,601

ORGANIZATION, DESCRIPTION OF BU

ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN	12 Months Ended
	Aug. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN	NOTE 1. ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN Entest Group, Inc. (the “Company” or “Entest”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. On July 12, 2009, the Company changed its name to Entest BioMedical, Inc. On February 12, 2018 the Company changed its name from Entest BioMedical, Inc. to Entest Group, Inc. The Company’s current business strategy is to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders. Change of Control On November 15, 2018, David Koos, Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and Peiwen Yu (the “Buyer”) entered into a stock purchase agreement (the “SPA”), pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of 23,733,334 shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA preferred stock and 1,001,533 shares of Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $325,000. The closing of the transactions contemplated by the SPA occurred on November 27, 2018. The purchase price was paid out of the Buyer’s personal funds. As of the date of the transaction, Entest had 49,170,472 shares of common stock, 728,073 shares of Series B Preferred Stock, 667 shares of Series AA Preferred Stock, 534 shares of Series AAA Preferred Stock and 1,001,533 shares of Non-Voting Convertible Preferred Stock outstanding. The securities purchased pursuant to the SPA represent 48.3% of the outstanding shares of common stock, 90% of the outstanding shares of common stock assuming the conversion of the Non-Voting Convertible Preferred Stock on the execution date of the SPA and 94% of the voting power of Entest. As contemplated by the SPA, in November 2018, David Koos resigned as Chairman, Chief Executive Officer, President, Acting Chief Financial Officer and Secretary of Entest and Peiwen Yu became as a director, Chief Executive Officer and President of Entest. Pursuant to the SPA, in November 2018, Mr. Koos also resigned as a director of the Company upon compliance by Entest with information statement delivery requirements pursuant to Rule 14f-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Going Concern and Liquidity Considerations The accompanying audited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any revenues since the change of control and disposition of its subsidiaries and has an accumulated deficit of $10,064,508. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future and repay its liabilities arising from normal business operations as they become due. In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Aug. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The audited financial statements have been prepared and presented in conformity with accounting principles generally accepted in the United States (“GAAP”) applicable to annual financial information and with the instructions to Form 10-K and regulation of the Securities and Exchange Commission (“SEC”). The annual financial information has been prepared on a basis consistent with prior years and includes all disclosures that are necessary and required by applicable laws and regulations. The audited financial statements and notes are presented in accordance with accounting principles generally accepted in the United States of America (GAAP) and are presented in U.S. dollars. These annual financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Basis of Consolidation The consolidated financial statements for the year ended August 31, 2018, include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statements also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated. During the year ended August 31, 2019, the entities were deconsolidated (see Notes 3, 5 and 6). Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. Cash and Cash Equivalents Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company had $0 and $267 in cash at August 31, 2019 and 2018, respectively. Fair Value Measurements As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The Company's financial instruments consist of interest receivable, accounts payable, and due to related parties. The carrying amounts of these financial instruments approximate fair value due to either length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. Basic and Diluted Net Income (Loss) per Common Share We compute basic and diluted earnings (loss) per share amounts in accordance with ASC Topic 260, “ Earnings per Share For the year ended August 31, 2019 and 2018, respectively, the following common stock equivalents were potentially dilutive. Years ended August 31, 2019 2018 (Shares) (Shares) Non-Voting Convertible Preferred Stock 71,538,071 96,807,783 For the year ended August 31, 2018, we excluded the computation of diluted net loss per share as the result of the computation was anti-dilutive, therefore, the diluted loss per share is the same as basic loss per share. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) "Leases." Topic 842 supersedes the lease recognition requirements in Accounting Standards Codification (“ASC”) Topic 840 "Leases." Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. Topic 842 is effective for annual reporting periods and interim periods within those years beginning after 15 December 2018. Early adoption by public entities is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and there are certain optional practical expedients that an entity may elect to apply. Full retrospective application is prohibited. The Company does not anticipate this amendment to have a significant impact on the financial statements. In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements. In February 2018, the FASB issued ASU No. 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this ASU address a narrow-scope financial reporting issue related to the tax effects that may become “stranded” in accumulated other comprehensive income (AOCI) as a result of the Tax Cuts and Jobs Act (TCJA). The amendments in ASU 2018-02 are effective for all entities for fiscal years beginning after 15 December 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company does not anticipate this amendment to have a significant impact on the financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework –Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and removes certain fair value measurement disclosure requirements. ASU 2018-13 is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Aug. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3. RELATED PARTY TRANSACTIONS On July 3, 2018, Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018. On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November, 2018. David R. Koos, who served as Chairman and Chief Executive Officer of Zander as of that date also served as Chairman and Chief Executive Officer of Entest as of that date. Zander was under common control with Entest as of that date. On November 16, 2018, Entest Group, Inc. and its then Chairman and Chief Executive Officer, David R. Koos, agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to David R. Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. Entest Group, Inc. and Blackbriar Partners (“BP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the Company’s inception to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos, as of that date, the Company’s then Chairman and Chief Executive Officer. Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the Company’s inception to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and BMSN. Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and RGBP. In November 2018, the Company divested itself of Entest BioMedical, Inc., a California corporation, for consideration consisting of $2,000 paid by an entity controlled by David R. Koos. The Company recognized a loss of $947 on the disposition based on the difference between the Net Assets of the subsidiary and the consideration paid. During the year ended August 31, 2019, the Company’s sole officer advanced to the Company an amount of $21,197 for the payment of operating expenses on behalf of the Company. As of August 31, 2019, and 2018, the Company was obligated to the officer, for an unsecured, non-interest bearing demand loan with a balance of $21,197 and $0, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Aug. 31, 2019
Stockholders' Deficit
STOCKHOLDERS EQUITY	NOTE 4. STOCKHOLDERS’ EQUITY Authorized Stock The Company is authorized to issue an aggregate of 500,000,000 shares of common stock with a par value of $0.0001, 5,000,000 shares of preferred stock with a par value of $0.0001, and 3,000,000 shares of non-voting convertible preferred stock with a par value of $1.00. Each share of common stock entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. Series AA Preferred Stock The Company is authorized to issue 100,000 shares of Series AA Preferred Stock at a par value of $0.0001 per share. As of August 31, 2019, and August 31, 2018, 667 shares of Series AA Preferred Stock were issued and outstanding. Series B Preferred Stock The Company is authorized to issue 4,400,000 shares of Series B Preferred Stock at a par value of $0.0001 per share. As of August 31, 2019, and August 31, 2018, 728,009 shares of Series B Preferred Stock were issued and outstanding. Series AAA Preferred Stock The Company is authorized to issue 300,000 shares of Series AAA Preferred Stock at a par value of $0.0001 per share. As of August 31, 2019, and August 31, 2018, 534 shares of Series AAA Preferred Stock were issued and outstanding. Non-Voting Convertible Preferred Stock The Company is authorized to issue 3,000,000 shares of Non-Voting Convertible Preferred Stock at a par value of $1.00 per share. On October 2, 2018, the Company amended Article 4 of its Articles of Incorporation to change the conversion features of the Company’s Non -Voting Convertible Preferred Stock. The Conversion Price changed from being equal to the greater of $0.01 per share or seventy percent (70%) of the lowest closing bid price of its shares of common stock (the “Closing Price”) on its principal trading market or exchange for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert to being equal to the greater of (i) $0.001 per share and (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert. As of August 31, 2019, and August 31, 2018, 1,001,533 shares of Non-Voting Convertible Preferred Stock were issued and outstanding. Common Shares The Company is authorized to issue 500,000,000 shares of Common Stock at a par value of $0.0001 per share. As of August 31, 2019, and August 31, 2018, 49,171,083 shares of Common Stock were issued and outstanding.

DECONSOLIDATION OF ZANDER THERA

DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.	12 Months Ended
	Aug. 31, 2019
Notes to Financial Statements
DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.	NOTE 5. DECONSOLIDATION OF ZANDER THERAPEUTICS, INC. On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to: (a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018. (b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018. Shareholders of the Company shall receive one (1) share of common stock of Zander Therapeutics, Inc. for each 17 shares of the Company’s common and/or preferred stock held as of the record date for such dividend. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 (“Distribution Date”). As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distributio Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034 gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the then Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which was a company under common control with Entest. The Company’s remaining shares of Zander, which consisted of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) were accounted for under the Equity Method as of the Distribution Date until November 29, 2018. The Zander M Stock was carried a Fair Value and the carrying value was increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value. As of August 31, 2018, the carrying value of the Zander M Stock was decreased by the Company’s proportionate share of the losses of Zander and was 0. As of August 31, 2018, Entest beneficially owned 34.82% of the share equity of Zander. During the quarter ended November 30, 2018, the Company divested itself of the Zander M Stock as satisfaction of $179,318 of interest accrued but unpaid owed by the Company and $9,270 of unearned rental payments made to the Company. As the Zander M Stock had a carrying value of $0, the Company recognized a gain of $188,589 on the disposition.

DISPOSITION OF ENTEST BIOMEDICA

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION	12 Months Ended
	Aug. 31, 2019
Disposition Of Entest Biomedical Inc. California Corporation
DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION	NOTE 6. DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION During the quarter ended November 30, 2018 the Company divested itself of Entest Biomedical, Inc., a California corporation and wholly owned subsidiary, for consideration consisting of $2,000 paid by an entity controlled by the Company’s then Chairman and Chief Executive Officer, David R. Koos, as full consideration for Entest Biomedical Inc. as well as any and all furniture, fixtures and equipment owned by the Company which has a carrying amount of $0. The Company recognized a loss of $947 on the disposition based on the difference between the Net Assets of the subsidiary and the Consideration paid. Cash derecognized in Divestiture $ (63 ) Accrued Rent Receivable Derecognized in Divestiture $ (6,000 ) Liabilities Derecognized in Divestiture $ 3,116 Consideration Received in Divestiture $ 2,000 Loss Recognized in Divestiture $ (947 )

INCOME TAXES

INCOME TAXES	12 Months Ended
	Aug. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7. INCOME TAXES The Company provides for income taxes under ASC 740, “Income Taxes.” The income tax provision for the years ended August 31, 2019 and 2018, consists of the following: August 31, August 31, 2019 2018 Net income (loss) $ 191,618 $ (1,477,484 ) Effective tax rate 21 % 21 % Income tax expense (benefit) 40,240 (310,272 ) Less: valuation allowance (40,240 ) 310,272 Income tax expense (benefit) $ - $ - Net deferred tax assets consist of the following components as of August 31, 2019 and 2018: August 31, August 31, 2019 2018 Net operating tax carryforwards $ 5,963 $ 2,156,652 Valuation allowance (5,963 ) (2,156,652 ) Net deferred tax asset $ - $ - On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may have, the legislation affects the way we can use and carry forward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects of the Act during the year ended August 31, 2019. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no impact on the balance sheet. At August 31, 2019 and 2018, the Company had $28,393 and $10,269,773 respectively of the U.S. net operating losses (the “U.S. NOLs”), which begin to expire beginning in 2029. NOLs generated in tax years prior to July 31, 2018, can be carryforward for twenty years, whereas NOLs generated after July 31, 2018 can be carryforward indefinitely. The NOL carry forwards are subject to certain limitations due to the change in control of the Company pursuant to Internal Revenue Code Section 382. The Company experienced a change in control for tax purposes in November 2018 (see Note 1). Due to change of control, the Company will not be able to carryover approximately $10,050,000 of NOL generated before November 27, 2018 to offset future income.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Aug. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of August 31, 2019 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Aug. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The audited financial statements have been prepared and presented in conformity with accounting principles generally accepted in the United States (“GAAP”) applicable to annual financial information and with the instructions to Form 10-K and regulation of the Securities and Exchange Commission (“SEC”). The annual financial information has been prepared on a basis consistent with prior years and includes all disclosures that are necessary and required by applicable laws and regulations. The audited financial statements and notes are presented in accordance with accounting principles generally accepted in the United States of America (GAAP) and are presented in U.S. dollars. These annual financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements for the year ended August 31, 2018, include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statements also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated. During the year ended August 31, 2019, the entities were deconsolidated (see Notes 3, 5 and 6).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company had $0 and $267 in cash at August 31, 2019 and 2018, respectively.
Fair Value Measurements	Fair Value Measurements As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The Company's financial instruments consist of interest receivable, accounts payable, and due to related parties. The carrying amounts of these financial instruments approximate fair value due to either length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.
Basic and Diluted Net Income (Loss) per Common Share	Basic and Diluted Net Income (Loss) per Common Share We compute basic and diluted earnings (loss) per share amounts in accordance with ASC Topic 260, “ Earnings per Share For the year ended August 31, 2019 and 2018, respectively, the following common stock equivalents were potentially dilutive. Years ended August 31, 2019 2018 (Shares) (Shares) Non-Voting Convertible Preferred Stock 71,538,071 96,807,783 For the year ended August 31, 2018, we excluded the computation of diluted net loss per share as the result of the computation was anti-dilutive, therefore, the diluted loss per share is the same as basic loss per share.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) "Leases." Topic 842 supersedes the lease recognition requirements in Accounting Standards Codification (“ASC”) Topic 840 "Leases." Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. Topic 842 is effective for annual reporting periods and interim periods within those years beginning after 15 December 2018. Early adoption by public entities is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and there are certain optional practical expedients that an entity may elect to apply. Full retrospective application is prohibited. The Company does not anticipate this amendment to have a significant impact on the financial statements. In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements. In February 2018, the FASB issued ASU No. 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this ASU address a narrow-scope financial reporting issue related to the tax effects that may become “stranded” in accumulated other comprehensive income (AOCI) as a result of the Tax Cuts and Jobs Act (TCJA). The amendments in ASU 2018-02 are effective for all entities for fiscal years beginning after 15 December 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company does not anticipate this amendment to have a significant impact on the financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework –Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and removes certain fair value measurement disclosure requirements. ASU 2018-13 is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Aug. 31, 2019
Accounting Policies [Abstract]
Schedule of Basic and Diluted Net Income (Loss) per Common Share	Years ended August 31, 2019 2018 (Shares) (Shares) Non-Voting Convertible Preferred Stock 71,538,071 96,807,783

DISPOSITION OF ENTEST BIOMEDI_2

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Tables)	12 Months Ended
	Aug. 31, 2019
Disposition Of Entest Biomedical Inc. California Corporation
Schedule of disposion	Cash derecognized in Divestiture $ (63 ) Accrued Rent Receivable Derecognized in Divestiture $ (6,000 ) Liabilities Derecognized in Divestiture $ 3,116 Consideration Received in Divestiture $ 2,000 Loss Recognized in Divestiture $ (947 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of income tax provision	August 31, August 31, 2019 2018 Net income (loss) $ 191,618 $ (1,477,484 ) Effective tax rate 21 % 21 % Income tax expense (benefit) 40,240 (310,272 ) Less: valuation allowance (40,240 ) 310,272 Income tax expense (benefit) $ - $ -
Schedule of deferred tax assets	August 31, August 31, 2019 2018 Net operating tax carryforwards $ 5,963 $ 2,156,652 Valuation allowance (5,963 ) (2,156,652 ) Net deferred tax asset $ - $ -

ORGANIZATION, DESCRIPTION OF _2

ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN (Detail Textuals) - USD ($)	Nov. 15, 2018	Aug. 31, 2019	Aug. 31, 2018
Number of common stock issued		49,171,083	49,171,083
Common stock, shares outstanding	49,170,472	49,171,083	49,171,083
Accumulated deficit		$ (10,064,508)	$ (10,256,126)
Series AA
Number of preferred stock issued		667	667
Preferred stock, shares outstanding	667	667	667
Series AAA
Number of preferred stock issued		534	534
Preferred stock, shares outstanding	534	534	534
Non-Voting Convertible Preferred Stock
Number of preferred stock issued		1,001,533	1,001,533
Preferred stock, shares outstanding	1,001,533	1,001,533	1,001,533
Series B
Number of preferred stock issued		728,073	728,073
Preferred stock, shares outstanding	728,073	728,073	728,073
Stock Purchase Agreement | Peiwen Yu
Number of common stock issued	23,733,334
Purchase price	$ 325,000
Stock Purchase Agreement | Peiwen Yu | Series AA
Number of preferred stock issued	667
Stock Purchase Agreement | Peiwen Yu | Series AAA
Number of preferred stock issued	534
Stock Purchase Agreement | Peiwen Yu | Non-Voting Convertible Preferred Stock
Number of preferred stock issued	1,001,533
Stock Purchase Agreement | Peiwen Yu | Common Stock
Percentage of Stock outstanding	48.30%
Stock Purchase Agreement | Peiwen Yu | Non-Voting Convertible Preferred Stock
Percentage of Stock outstanding	90.00%
Stock Purchase Agreement | Peiwen Yu | Voting common stock
Percentage of Stock outstanding	94.00%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Non-Voting Convertible Preferred Stock
Dilutive common stock equivalents	71,538,071	96,807,783

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)	Aug. 31, 2018USD ($)
Accounting Policies [Abstract]
Cash	$ 267

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	Jul. 03, 2018	Nov. 30, 2018	Aug. 31, 2019
Loss on disposition			$ 188,589
Divestiture consideration			2,000
Due to related party			21,197
Gain (Loss) on Disposition of Assets			(947)
Unsecured and non-interest bearing loan
Due to related party		$ 0	$ 21,197
David R. Koos
Divestiture consideration		$ 2,000
David R. Koos | Zander M Stock
Number of shares issued		3,000,000
Zander Therapeutics, Inc.
Monthly Sublease income	$ 6,000
Blackbriar Partners ("BP") | Zander M Stock
Number of shares issued		20,000
Bio Matrix Scientific Group, Inc. ("BMSN") | Zander M Stock
Number of shares issued		5,000
Regen Biopharma, Inc. ("RGBP") | Zander M Stock
Number of shares issued		250,000
Number of shares issued for prepaid rent		475,000

STOCKHOLDERS' EQUITY (Detail Te

STOCKHOLDERS' EQUITY (Detail Textuals) - $ / shares	Oct. 02, 2018	Aug. 31, 2019	Nov. 15, 2018	Aug. 31, 2018
Common stock, par value		$ 0.0001		$ 0.0001
Common stock, shares authorized		500,000,000		500,000,000
Common stock, shares issued		49,171,083		49,171,083
Common stock, shares outstanding		49,171,083	49,170,472	49,171,083
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		5,000,000		5,000,000
Non-Voting Convertible Preferred Stock
Preferred stock, par value		$ 1		$ 1
Preferred stock, shares authorized		3,000,000		3,000,000
Preferred stock, shares issued		1,001,533		1,001,533
Preferred stock, shares outstanding		1,001,533	1,001,533	1,001,533
Liquidation terms	(i) $0.001 per share and (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder's intent to convert.
Conversion price reduction due to closing bid price (in dollar per share)	$ 0.01
Conversion price equals average closing bid price (percent)	70.00%
Number of consecutive trading days	5 days
Series AA
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		100,000		100,000
Preferred stock, shares issued		667		667
Preferred stock, shares outstanding		667	667	667
Series B
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		4,400,000		4,400,000
Preferred stock, shares issued		728,073		728,073
Preferred stock, shares outstanding		728,073	728,073	728,073
Series AAA
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		300,000		300,000
Preferred stock, shares issued		534		534
Preferred stock, shares outstanding		534	534	534

DECONSOLIDATION OF ZANDER THE_2

DECONSOLIDATION OF ZANDER THERAPEUTICS, INC. (Detail Textuals) - USD ($)	May 05, 2018	Aug. 31, 2018	Aug. 31, 2019	Nov. 30, 2018
Common stock, par value		$ 0.0001	$ 0.0001
Gain on deconsolidation		$ 10,034
Interest accrued		1,040
Zander M Stock
Gain on deconsolidation		188,589
Equity method stock remaining	5,000,000
Carrying value		$ 0
Zander Therapeutics, Inc.
Dividend in kind	3,000,000
Common stock, par value	$ 0.0001
Record date	May 30, 2018
Distribution date	Jun. 11, 2018
Gain on deconsolidation	$ 10,034
Ownership percentage		34.82%
Interest accrued				$ 179,318
Unearned rental payments				$ 9,270
Common stock distribution description	one (1) share of common stock of Zander Therapeutics, Inc. for each 17 shares of the Company's common and/or preferred stock

DISPOSITION OF ENTEST BIOMEDI_3

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Details)	12 Months Ended
	Aug. 31, 2019USD ($)
Consideration Received in Divestiture	$ 2,000
Loss Recognized in Divestiture	(947)
Entest Biomedical, Inc.
Cash derecognized in Divestiture	(63)
Accrued Rent Receivable Derecognized in Divestiture	(6,000)
Liabilities Derecognized in Divestiture	3,116
Consideration Received in Divestiture	2,000
Loss Recognized in Divestiture	$ (947)

DISPOSITION OF ENTEST BIOMEDI_4

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Detail Textuals)	12 Months Ended
	Aug. 31, 2019USD ($)
Disposition Of Entest Biomedical Inc. California Corporation
Divestiture consideration	$ 2,000
Furniture fixtures and equipment carrying amount	0
Loss on disposition Entest Biomedical	$ (947)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Income Taxes
Net income (loss)	$ 191,618	$ (1,477,484)
Effective tax rate	21.00%	21.00%
Income tax expense (benefit)	$ 40,240	$ (310,272)
Less: valuation allowance	(40,240)	310,272
Income tax expense (benefit)	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Aug. 31, 2019	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Net operating tax carryforwards	$ 5,963	$ 2,156,652
Valuation allowance	(5,963)	(2,156,652)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals) - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Income Tax [Line Items]
Net operating loss carry forwards	$ 28,393	$ 10,269,773
Description of carry forwards expiry year	which begin to expire beginning in 2029
Net operating loss carryforward generated before offset future income	$ 10,050,000
Previous Tax Year
Income Tax [Line Items]
Effective interest tax rate	34.00%
Current Tax Year
Income Tax [Line Items]
Effective interest tax rate	21.00%